MTS Health Partners

What MTS Health Partners does

MTS Health Partners, L.P. is a privately-held boutique investment bank founded in 1999 by Curtis S. Lane that provides strategic and financial advisory services exclusively to the healthcare industry. Headquartered in New York (623 Fifth Avenue, 14th Floor) with an additional office in Tokyo, the firm operates with 85+ professionals and has executed 303+ transactions representing over $132 billion of aggregate client value across 25+ years. Its service offering spans core strategic advisory — mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, fairness opinions, and general strategic counsel — alongside a financing practice covering private convertible preferred issuances, crossover convertibles, common stock and structured/convertible PIPEs, registered direct financings, acquisition financings, secondary sales, special situations, and structured debt / royalty monetizations. Securities-related services are delivered through a wholly-owned FINRA/SIPC-member affiliate, MTS Securities, LLC.

The firm serves healthcare-focused counterparties across biopharmaceuticals, life science tools and diagnostics, medical technology, data-driven healthcare technology, and healthcare services, addressing both global corporations and venture-backed businesses. Its go-to-market is relationship-driven: senior bankers originate mandates directly through long-tenured networks, and the firm explicitly positions itself as a transaction-agnostic advisor pursuing all available strategic alternatives rather than favoring specific structures. The revenue model is professional services — transaction-based success fees, retainers, and hybrid billing on a multi-year engagement cadence — with pricing negotiated per mandate rather than published. Marquee recent mandates include Seagen/Pfizer ($43bn, 2023), Chinook Therapeutics/Novartis ($3.2bn, 2023), Pharmacosmos/G1 Therapeutics ($405m, 2024), Taiho/Araris ($1.14bn, 2025), Galapagos/Gilead ($1.1bn, 2026), and Knox Lane/Cross Country Healthcare ($437m, 2026).

Name

MTS Health Partners

Legal name

MTS Health Partners, L.P.

Website

https://mtspartners.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

51–100 employees

Short description

MTS Health Partners, L.P. is a privately-held, New York–headquartered boutique investment bank providing strategic M&A advisory and private financing services exclusively to the healthcare industry across biopharma, medtech, life sciences, health tech, and healthcare services.

Ownership category

akta.pro rank

Product category

Healthcare Investment Banking & M&A Advisory

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Miscellaneous Business Credit Institution (6159)

akta.pro primary industry

Private Placements (144A/Reg S/MTN) (FSACABAK)

Keywords

• Healthcare M&A advisory
• Boutique investment banking
• Strategic advisory services
• Healthcare financing solutions
• Fairness opinions

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Strategic Advisory Services: M&A advisory, company sales, divestitures, mergers, recapitalizations, restructurings, fairness opinions, and general strategic advice to healthcare companies.
2. Financing Services: Equity and structured financing including private convertible preferred issuances, crossover convertible transactions, common stock and structured/convertible PIPEs, registered direct financings, acquisition financings, secondary sales, special situations, and structured debt financings and royalty monetizations.
3. Securities Services: Securities offered through MTS Securities, LLC, an affiliate providing broker-dealer services. Member FINRA/SIPC.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

MTS Health Partners is a boutique investment bank that provides strategic and financial advisory services exclusively to the healthcare industry. Its core offerings include M&A advisory (mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings), fairness opinions, and private financing capabilities (convertible preferred issuances, PIPE transactions, registered direct financings, acquisition financings, secondary sales, structured debt and royalty monetizations) for both public and private healthcare companies.

Product overview

MTS Health Partners is a boutique investment bank offering strategic and financial advisory services exclusively to the healthcare industry. The firm provides a unified set of advisory services centered on M&A transactions, company sales, divestitures, recapitalizations, restructurings, fairness opinions, and general strategic advice. Additionally, MTS offers financing capabilities including private convertible preferred issuances, PIPE transactions, registered direct financings, acquisition financings, secondary sales, special situations, and structured debt financings and royalty monetizations. Services span across biopharmaceuticals, life science tools and diagnostics, medical technology, data-driven healthcare technology, and healthcare services sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic Advisory Services Senior-led strategic counsel for healthcare companies on mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, financing oversight, general strategic advice, and fairness opinions, delivered in the context of long-term client relationships across biopharmaceuticals, life science tools and diagnostics, medical technology, data-driven healthcare technology, and healthcare services sectors.
• Financing Capabilities Capital raising services for public and private healthcare companies, including traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct financings, acquisition financings, secondary sales, special situations, and structured debt financings and royalty monetizations, delivered through differentiated execution and strong investor relationships.
• Fairness Opinions Independent fairness opinions provided to boards of directors of healthcare companies in connection with strategic transactions, leveraging the firm's healthcare sector expertise and objective advisor positioning.

Quantifiable outcome

• 303+ transactions executed representing over $132 billion of value
• +1 more outcomes

Named customers8 records

Segments7 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• MTS Securities, LLCcoreOthersMTS Securities, LLC is an affiliated broker-dealer of MTS Health Partners, L.P. Securities offered through MTS Securities, LLC, which is a member of FINRA and SIPC. The affiliate provides securities services complementary to the firm's investment banking advisory and financing capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Leerink Partners (formerly SVB Leerink): Healthcare-focused boutique investment bank providing M&A advisory and equity research to biopharma, medtech and healthcare services clients. The closest direct competitor to MTS in pure-play healthcare advisory, with overlapping mid-market and growth-stage biopharma coverage.
• Centerview Partners: Elite independent advisory firm with a dedicated healthcare practice advising on large-cap M&A and strategic transactions. Overlaps with MTS on biopharma and medtech sell-side mandates but operates at generally larger average deal sizes and fewer, larger teams per engagement.
• Guggenheim Partners (Healthcare Group): Diversified financial services firm with a dedicated Healthcare Investment Banking group covering biopharma, diagnostics and medical devices. A direct competitor to MTS on healthcare M&A mandates, with broader capital markets capabilities (DCM, ECM) supporting financing-driven processes.
• William Blair (Healthcare Group): Employee-owned boutique with a longstanding Healthcare Investment Banking practice advising growth-stage and mid-market biopharma, medtech and diagnostics companies. Closely comparable to MTS in size, healthcare focus and growth-company client base.
• Robert W. Baird (Healthcare Group): Employee-owned global investment bank with a Healthcare Investment Banking franchise advising on M&A and equity financings for biopharma, medical technology and healthcare services. Comparable to MTS on mid-market healthcare sell-side mandates and capital raises.
• Perella Weinberg Partners: Independent advisory firm with an active Healthcare practice advising on biopharma, medtech and healthcare services M&A. Competes with MTS on healthcare sell-side mandates, generally at the upper end of the mid-market and in selected large-cap situations.
• Greenhill & Co. Independent M&A advisory boutique with healthcare sector coverage across biopharma, medtech and services. Comparable in boutique scale and senior-led model to MTS, though Greenhill operates as a generalist with healthcare as one of several core verticals.

Broad incumbents

• Jefferies Healthcare Group: Mid-market focused full-service investment bank with a sizeable Healthcare Investment Banking franchise spanning biotech, medtech, diagnostics and healthcare services. Competes with MTS across mid- and large-cap healthcare M&A but offers materially broader financing and capital markets capabilities.
• Lazard (Healthcare Group): Global elite advisory firm with a large Healthcare practice advising on pharma, biotech, medtech and services M&A globally. Overlaps with MTS on large healthcare M&A mandates but offers materially greater international reach, restructuring and capital structure advisory.
• Evercore (Healthcare Group): Independent investment bank with a leading Healthcare Investment Banking franchise advising on biopharma, medtech and healthcare services M&A. Competes with MTS on premium healthcare mandates but at generally larger average deal sizes and with broader restructuring expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mts-health-partners-l-p-
• Xx.com/mtspartners

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MTS Health Partners